Minerva Biotechnologies Gets FDA Approval of IND for a MUC1*-CAR-1XX with Increased Persistence and Ability to Kill Low Antigen Expressing Cells for Treatment of Solid Tumor Cancers
Retrieved on:
Monday, January 9, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, Clinical trial, Investigational New Drug, Progressive disease, Courage, Phosphorylation, Metastasis, CAR, Growth, Patient, Tyrosine, MUC1, FDA, IND, Recurrence, Biotechnology, Partial-response maximum-likelihood, Memorial Sloan Kettering Cancer Center, Pharmaceutical industry, Vaccine, Phenylalanine
huMNC2-CAR22 targets MUC1* (muk 1 star), the growth factor receptor that drives the growth and metastasis of most solid tumor cancers.
Key Points:
- huMNC2-CAR22 targets MUC1* (muk 1 star), the growth factor receptor that drives the growth and metastasis of most solid tumor cancers.
- Minerva’s first CAR T that targets MUC1*, huMNC2-CAR44, is already in a clinical trial for metastatic breast cancers.
- However, for a durable response, we needed to overcome CAR T cell exhaustion, which is common to CAR T cell treatment of solid tumor cancers.
- Unexpectedly, the 1XX mutations give the CAR T cells the added benefit of being able to recognize and kill the low antigen expressing cancer cells that lead to cancer recurrence.